News Archive

2018

August

Media Release / Aug 23, 2018

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

Read More
Media Release / Aug 14, 2018

Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

Read More

July

Media Release / Jul 30, 2018

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Read More
Media Release / Jul 27, 2018

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Read More
Media Release / Jul 27, 2018

Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma

Read More
Media Release / Jul 23, 2018

Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke

Read More
Media Release / Jul 19, 2018

Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis

Read More
Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

June

Media Release / Jun 29, 2018

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe

Read More

Pages

Related Links